CUE
Cue Biopharma, Inc.
stockNASDAQ
cue biopharma is an innovative immunotherapy company developing a novel, proprietary class of biologics engineered to selectively modulate the human immune system to treat a broad range of cancers and autoimmune disorders. we design biologics to engage and modulate the activity of disease-associated t cells in the patient's body, offering significant therapeutic advantages while potentially minimizing or eliminating unwanted side effects. we believe our biologics allow us to target antigen-specific t cell populations in a variety of indications using a simple peptide exchange within previously-validated drug frameworks developed from the cue biologics platform. this flexibility could truncate the drug selection and development process, moving effective therapeutics from discovery to clinical validation more rapidly and cost efficiently than current industry standard timelines and costs. headquartered in kendall square, cambridge, ma, we are led by an experienced management team and sci
| Period | Price | Date | Change | Beta |
|---|---|---|---|---|
| 1W | 27.45 | 2026-09-28 | -6.79% | 4.132 |
| 1M | 27.44 | 2026-09-04 | -6.76% | -3.126 |
| 3M | 32.50 | 2026-07-06 | -21.27% | 0.527 |
| 6M | 5.31 | 2026-04-06 | +381.83% | 3.672 |
| 1Y | 21.87 | 2025-10-03 | +16.97% | 2.760 |
| 2Y | 34.80 | 2024-10-04 | -26.48% | — |
| 5Y | 390.00 | 2021-10-04 | -93.44% | 1.521 |
Cue Biopharma, Inc. (NASDAQ:CUE) stock price today is $25.59, and today's volume is 157,037. CUE is up 1.327% today. The 30 day average volume is 348,490. CUE market cap is $185.86M with 7.26M shares outstanding.